Evidence map›Paper›PMID 32061674›Full record

ReviewMethods (San Diego, Calif.)2020

From laboratory to clinic: Translation of extracellular vesicle based cancer biomarkers.

Anudeep Yekula, Koushik Muralidharan, Keiko M Kang, Lan Wang, Leonora Balaj, Bob S Carter

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Methods (San Diego, Calif.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. The RNA content of extracellular vesicles from gene-editedMolecular therapy. Methods & clinical development · 2025
    Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anudeep YekulaDepartment of Neurosurgery, Massachusetts General Hospital and Harvard Medical School and Harvard Medical School, Boston, MA, United States. Electronic address: ayekula@mgh.harvard.edu.
Koushik MuralidharanDepartment of Neurosurgery, Massachusetts General Hospital and Harvard Medical School and Harvard Medical School, Boston, MA, United States. Electronic address: KMURALIDHARAN@mgh.harvard.edu.
Keiko M KangDepartment of Neurosurgery, Massachusetts General Hospital and Harvard Medical School and Harvard Medical School, Boston, MA, United States; School of Medicine, University of California, San Diego, La Jolla, CA, United States. Electronic address: KMKANG@mgh.harvard.edu.
Lan WangDepartment of Neurosurgery, Massachusetts General Hospital and Harvard Medical School and Harvard Medical School, Boston, MA, United States. Electronic address: LWANG60@mgh.harvard.edu.
Leonora BalajDepartment of Neurosurgery, Massachusetts General Hospital and Harvard Medical School and Harvard Medical School, Boston, MA, United States. Electronic address: Balaj.Leonora@mgh.harvard.edu.
Bob S CarterDepartment of Neurosurgery, Massachusetts General Hospital and Harvard Medical School and Harvard Medical School, Boston, MA, United States. Electronic address: BCARTER@mgh.harvard.edu.

Funding

The role of microvesicles in giloma virotherapyP01CA069246 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHAREST, ALAIN · 1996 to 2021
$30.9M
Liquid Biopsy for treatment stratification of IDH1.R132H and EGFRvIII mutant gliomasU01CA230697 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CARTER, BOB S, SKOG, JOHAN · 2018 to 2022
$4.0M
exRNA Biomarkers for Human GliomaUH3TR000931 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CARTER, BOB S, HOCHBERG, FRED H · 2015 to 2017
$3.0M
NCATS NIH HHS UH3 TR000931NCI NIH HHS P01 CA069246NCI NIH HHS U01 CA230697
6 · The paper itself

Abstract

The past decade has witnessed a rapid growth in the field of extracellular vesicle (EV) based biomarkers for the diagnosis and monitoring of cancer. Several studies have reported novel EV based biomarkers, but the technical and clinical validation phase has been hampered by general challenges common to biomedical research field as well as specific challenges inherent to the nanoparticle field. This has led to more common failures than success stories in the biomarker discovery pipeline. As a result, more attention must be focused on the process of biomarker discovery, verification, and validation to allow for translation and application of novel EV based research to patient care. Herein, we briefly discuss the hurdles and potential solutions in EV biomarker discovery and verification and validation, and clinical translation.

Indexed as

Biomarkers, TumorExtracellular VesiclesHumansNasal CavityNeoplasmsReagent Kits, DiagnosticResearch DesignSalivaSensitivity and SpecificityTranslational Research, BiomedicalValidation Studies as TopicBiomarkers, TumorReagent Kits, DiagnosticBiomarker discoveryBiomarkersBiomarker validationCLIAClinical translationExtracellular vesicles

Identifiers

PMID32061674
PMCPMC7198349

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.